J Cancer 2019; 10(25):6431-6438. doi:10.7150/jca.32691

Research Paper

Liensinine inhibited gastric cancer cell growth through ROS generation and the PI3K/AKT pathway

Jia-hua Yang*, Kun Yu*, Xian-ke Si, Sen Li, Yi-jun Cao, Wei Li, Ji-xun Zhang

Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, 164 lanxi Rd, Shanghai, 200062, China.
*Contributed equally to the work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Yang Jh, Yu K, Si Xk, Li S, Cao Yj, Li W, Zhang Jx. Liensinine inhibited gastric cancer cell growth through ROS generation and the PI3K/AKT pathway. J Cancer 2019; 10(25):6431-6438. doi:10.7150/jca.32691. Available from http://www.jcancer.org/v10p6431.htm

File import instruction

Abstract

Liensinine, an isoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera Gaertn, has been shown to exhibit various phrenological effects, including anti‑cancer activity. The aim of this study is to investigate the effects and mechanisms of liensinine in human gastric cancer cells. In this study, we found liensinine can significantly inhibit gastric cancer cell proliferation in vitro and in vivo. Liensinine inducedgastric cancer cell apoptosis by increasing cleaved PARP, caspased 3 and caspased 9. Moreover, liensinine induced cycle arrest by downregulatingcyclinD1/cyclin‑dependent kinase4 and phosphorylated protein kinase B. Furthermore, we found liensinine increases ROS levels and inhibits the PI3K/AKT pathway. These data suggested that liensinine might represent a novel and effective agent against gastric cancer.

Keywords: liensinine, gastric cancer, cell proliferation, ROS.